Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

Related Content:

State of the Science Summit on Genitourinary CancersOncLive TVProstate Cancer
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL
Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL